Intra-Cellular Therapies Inc (ITCI)

Healthcare Pharmaceuticals & Medical Research Biotechnology & Medical Research

Track Share on 𝕏

Stock chart
Ticker: ITCI Exchange: NSM


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale
Past 90 days
 
Value bought
 
Value sold
 
Net insiders buying
 
Trades (buy and sell)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PS: Planned sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Total value Details
2024-03-11 2024-03-11 PS Planned sale

Durgam Suresh K.

EVP, Chief Medical Officer

Officer
661 -3.2%
66.96
44,261 USD 		661 -3.2% 66.96 44,261 USD
2024-03-11 2024-03-11 PS Planned sale

Durgam Suresh K.

EVP, Chief Medical Officer

Officer
872 -4.1%
65.89
57,456 USD 		872 -4.1% 65.89 57,456 USD
2024-03-11 2024-03-11 PS Planned sale

Durgam Suresh K.

EVP, Chief Medical Officer

Officer
2,179 -9.3%
65.06
141,766 USD 		2,179 -9.3% 65.06 141,766 USD
2024-03-11 2024-03-11 PS Planned sale

Neumann Mark

EVP, Chief Commercial Officer

Officer
1,313 -4.2%
66.86
87,787 USD 		1,313 -4.2% 66.86 87,787 USD
2024-03-11 2024-03-11 PS Planned sale

Neumann Mark

EVP, Chief Commercial Officer

Officer
1,729 -5.3%
65.92
113,976 USD 		1,729 -5.3% 65.92 113,976 USD
2024-03-11 2024-03-11 PS Planned sale

Neumann Mark

EVP, Chief Commercial Officer

Officer
4,303 -11.6%
65.11
280,168 USD 		4,303 -11.6% 65.11 280,168 USD
2024-03-11 2024-03-11 PS Planned sale

Mates Sharon

Chairman, President & CEO

Executive Director
306 -0.0%
67.33
20,603 USD 		306 -0.0% 67.33 20,603 USD
2024-03-11 2024-03-11 PS Planned sale

Mates Sharon

Chairman, President & CEO

Executive Director
1,590 -0.2%
66.81
106,228 USD 		1,590 -0.2% 66.81 106,228 USD
2024-03-11 2024-03-11 PS Planned sale

Mates Sharon

Chairman, President & CEO

Executive Director
4,128 -0.4%
65.90
272,035 USD 		4,128 -0.4% 65.90 272,035 USD
2024-03-11 2024-03-11 PS Planned sale

Mates Sharon

Chairman, President & CEO

Executive Director
14,541 -1.4%
64.80
942,257 USD 		14,541 -1.4% 64.80 942,257 USD
2024-03-11 2024-03-11 PS Planned sale

Hineline Lawrence J.

SVP of Finance, CFO

Officer
64 -100.0%
67.12
4,296 USD 		64 -100.0% 67.12 4,296 USD
2024-03-11 2024-03-11 PS Planned sale

Hineline Lawrence J.

SVP of Finance, CFO

Officer
4,475 -98.6%
66.47
297,453 USD 		4,475 -98.6% 66.47 297,453 USD
2024-03-11 2024-03-11 PS Planned sale

Hineline Lawrence J.

SVP of Finance, CFO

Officer
29 -100.0%
67.32
1,952 USD 		29 -100.0% 67.32 1,952 USD
2024-03-11 2024-03-11 PS Planned sale

Hineline Lawrence J.

SVP of Finance, CFO

Officer
1,100 -97.4%
66.54
73,194 USD 		1,100 -97.4% 66.54 73,194 USD
2024-03-11 2024-03-11 PS Planned sale

Hineline Lawrence J.

SVP of Finance, CFO

Officer
4,453 -79.8%
65.28
290,692 USD 		4,453 -79.8% 65.28 290,692 USD
2024-03-11 2024-03-11 PS Planned sale

Halstead Michael

EVP and General Counsel

Officer
1,238 -100.0%
66.70
82,575 USD 		1,238 -100.0% 66.70 82,575 USD
2024-03-11 2024-03-11 PS Planned sale

Halstead Michael

EVP and General Counsel

Officer
6,107 -83.1%
65.82
401,963 USD 		6,107 -83.1% 65.82 401,963 USD
2024-03-11 2024-03-07 PS Planned sale

Durgam Suresh K.

EVP, Chief Medical Officer

Officer
2,722 -14.4%
66.86
181,993 USD 		2,722 -14.4% 66.86 181,993 USD
2024-03-11 2024-03-07 PS Planned sale

Durgam Suresh K.

EVP, Chief Medical Officer

Officer
3,728 -16.5%
66.34
247,316 USD 		3,728 -16.5% 66.34 247,316 USD
2024-03-11 2024-03-07 PS Planned sale

Neumann Mark

EVP, Chief Commercial Officer

Officer
4,496 -13.1%
66.95
301,007 USD 		4,496 -13.1% 66.95 301,007 USD
2024-03-11 2024-03-07 PS Planned sale

Neumann Mark

EVP, Chief Commercial Officer

Officer
8,636 -20.2%
66.37
573,171 USD 		8,636 -20.2% 66.37 573,171 USD
2024-03-11 2024-03-07 PS Planned sale

Mates Sharon

Chairman, President & CEO

Executive Director
8,754 -0.8%
66.93
585,905 USD 		8,754 -0.8% 66.93 585,905 USD
2024-03-11 2024-03-07 PS Planned sale

Mates Sharon

Chairman, President & CEO

Executive Director
31,958 -2.9%
66.38
2,121,372 USD 		31,958 -2.9% 66.38 2,121,372 USD
2024-03-11 2024-03-07 PS Planned sale

Hineline Lawrence J.

SVP of Finance, CFO

Officer
6,618 -100.0%
66.93
442,943 USD 		6,618 -100.0% 66.93 442,943 USD
2024-03-11 2024-03-07 PS Planned sale

Hineline Lawrence J.

SVP of Finance, CFO

Officer
6,514 -49.6%
66.26
431,618 USD 		6,514 -49.6% 66.26 431,618 USD
2024-03-11 2024-03-07 PS Planned sale

Halstead Michael

EVP and General Counsel

Officer
220 -100.0%
66.81
14,698 USD 		220 -100.0% 66.81 14,698 USD
2024-03-11 2024-03-07 PS Planned sale

Halstead Michael

EVP and General Counsel

Officer
12,912 -98.3%
66.14
854,000 USD 		12,912 -98.3% 66.14 854,000 USD
2024-02-28 2024-02-27 S Sale

VAN NOSTRAND ROBERT L

Non-Executive Director
10,349 -51.8%
73.14
756,926 USD 		10,349 -51.8% 73.14 756,926 USD
2024-02-28 2024-02-27 S Sale

VAN NOSTRAND ROBERT L

Non-Executive Director
9,651 -32.6%
72.71
701,724 USD 		9,651 -32.6% 72.71 701,724 USD
2024-02-27 2024-02-26 PS Planned sale

Hineline Lawrence J.

SVP of Finance, CFO

Officer
600 -100.0%
69.81
41,886 USD 		600 -100.0% 69.81 41,886 USD
2024-02-27 2024-02-26 PS Planned sale

Hineline Lawrence J.

SVP of Finance, CFO

Officer
5,282 -89.8%
69.47
366,941 USD 		5,282 -89.8% 69.47 366,941 USD
2024-02-27 2024-02-26 PS Planned sale

Hineline Lawrence J.

SVP of Finance, CFO

Officer
288 -100.0%
70.15
20,203 USD 		288 -100.0% 70.15 20,203 USD
2024-02-27 2024-02-26 PS Planned sale

Hineline Lawrence J.

SVP of Finance, CFO

Officer
6,867 -96.0%
69.38
476,432 USD 		6,867 -96.0% 69.38 476,432 USD
2024-02-27 2024-02-26 PS Planned sale

Hineline Lawrence J.

SVP of Finance, CFO

Officer
300 -4.0%
68.33
20,499 USD 		300 -4.0% 68.33 20,499 USD
2024-02-27 2024-02-26 PS Planned sale

Mates Sharon

Chairman, President & CEO

Executive Director
12,462 -1.2%
70.11
873,711 USD 		12,462 -1.2% 70.11 873,711 USD
2024-02-27 2024-02-26 PS Planned sale

Mates Sharon

Chairman, President & CEO

Executive Director
9,528 -0.9%
69.45
661,720 USD 		9,528 -0.9% 69.45 661,720 USD
2024-02-27 2024-02-26 PS Planned sale

Mates Sharon

Chairman, President & CEO

Executive Director
600 -0.1%
68.39
41,034 USD 		600 -0.1% 68.39 41,034 USD
2024-02-27 2024-02-26 S Sale

MARCUS JOEL S

Non-Executive Director
299 -0.7%
69.60
20,810 USD 		299 -0.7% 69.60 20,810 USD
2024-02-27 2024-02-26 S Sale

MARCUS JOEL S

Non-Executive Director
17,658 -30.6%
69.07
1,219,638 USD 		17,658 -30.6% 69.07 1,219,638 USD
2024-02-27 2024-02-26 S Sale

MARCUS JOEL S

Non-Executive Director
8,371 -12.7%
67.83
567,805 USD 		8,371 -12.7% 67.83 567,805 USD
2024-02-27 2024-02-26 PS Planned sale

Durgam Suresh K.

EVP, Chief Medical Officer

Officer
1,312 -12.1%
71.02
93,178 USD 		1,312 -12.1% 71.02 93,178 USD
2024-02-27 2024-02-26 PS Planned sale

Durgam Suresh K.

EVP, Chief Medical Officer

Officer
1,400 -11.5%
70.16
98,224 USD 		1,400 -11.5% 70.16 98,224 USD
2024-02-27 2024-02-26 PS Planned sale

Durgam Suresh K.

EVP, Chief Medical Officer

Officer
1,400 -10.3%
69.38
97,132 USD 		1,400 -10.3% 69.38 97,132 USD
2024-02-27 2024-02-26 PS Planned sale

Neumann Mark

EVP, Chief Commercial Officer

Officer
1,307 -4.2%
71.18
93,032 USD 		1,307 -4.2% 71.18 93,032 USD
2024-02-27 2024-02-26 PS Planned sale

Neumann Mark

EVP, Chief Commercial Officer

Officer
2,341 -7.0%
70.70
165,509 USD 		2,341 -7.0% 70.70 165,509 USD
2024-02-27 2024-02-26 PS Planned sale

Neumann Mark

EVP, Chief Commercial Officer

Officer
4,059 -10.9%
69.56
282,344 USD 		4,059 -10.9% 69.56 282,344 USD
2024-02-27 2024-02-26 PS Planned sale

Neumann Mark

EVP, Chief Commercial Officer

Officer
200 -0.5%
68.03
13,606 USD 		200 -0.5% 68.03 13,606 USD
2024-02-27 2024-02-26 PS Planned sale

Halstead Michael

EVP and General Counsel

Officer
392 -100.0%
70.13
27,491 USD 		392 -100.0% 70.13 27,491 USD
2024-02-27 2024-02-26 PS Planned sale

Halstead Michael

EVP and General Counsel

Officer
7,215 -94.8%
69.54
501,731 USD 		7,215 -94.8% 69.54 501,731 USD
2024-02-27 2024-02-26 PS Planned sale

Halstead Michael

EVP and General Counsel

Officer
300 -3.8%
68.54
20,562 USD 		300 -3.8% 68.54 20,562 USD
2024-02-05 2024-02-02 PS Planned sale

Mates Sharon

Chairman, President & CEO

Executive Director
17,450 -1.6%
67.42
1,176,479 USD 		17,450 -1.6% 67.42 1,176,479 USD
2024-02-05 2024-02-02 PS Planned sale

Mates Sharon

Chairman, President & CEO

Executive Director
16,435 -1.5%
66.70
1,096,215 USD 		16,435 -1.5% 66.70 1,096,215 USD
2024-02-05 2024-02-02 PS Planned sale

Neumann Mark

EVP, Chief Commercial Officer

Officer
6,904 -18.9%
67.49
465,951 USD 		6,904 -18.9% 67.49 465,951 USD
2024-02-05 2024-02-02 PS Planned sale

Neumann Mark

EVP, Chief Commercial Officer

Officer
4,956 -11.9%
66.67
330,417 USD 		4,956 -11.9% 66.67 330,417 USD
2024-02-05 2024-02-02 PS Planned sale

Halstead Michael

EVP and General Counsel

Officer
714 -100.0%
67.17
47,959 USD 		714 -100.0% 67.17 47,959 USD
2024-02-05 2024-02-02 PS Planned sale

Halstead Michael

EVP and General Counsel

Officer
11,146 -94.0%
66.37
739,760 USD 		11,146 -94.0% 66.37 739,760 USD
2024-02-05 2024-02-02 PS Planned sale

Durgam Suresh K.

EVP, Chief Medical Officer

Officer
3,847 -40.3%
67.49
259,634 USD 		3,847 -40.3% 67.49 259,634 USD
2024-02-05 2024-02-02 PS Planned sale

Durgam Suresh K.

EVP, Chief Medical Officer

Officer
2,320 -19.6%
66.69
154,721 USD 		2,320 -19.6% 66.69 154,721 USD
2024-02-05 2024-02-02 PS Planned sale

Hineline Lawrence J.

SVP of Finance, CFO

Officer
185 -100.0%
67.35
12,460 USD 		185 -100.0% 67.35 12,460 USD
2024-02-05 2024-02-02 PS Planned sale

Hineline Lawrence J.

SVP of Finance, CFO

Officer
10,998 -98.3%
66.61
732,577 USD 		10,998 -98.3% 66.61 732,577 USD
2024-01-18 2024-01-18 PS Planned sale

Mates Sharon

Chairman, President & CEO

Executive Director
320 -0.0%
66.25
21,200 USD 		320 -0.0% 66.25 21,200 USD
2024-01-18 2024-01-18 PS Planned sale

Mates Sharon

Chairman, President & CEO

Executive Director
67,597 -6.0%
65.19
4,406,648 USD 		67,597 -6.0% 65.19 4,406,648 USD
2024-01-18 2024-01-17 PS Planned sale

Mates Sharon

Chairman, President & CEO

Executive Director
17,451 -1.6%
66.66
1,163,284 USD 		17,451 -1.6% 66.66 1,163,284 USD
2024-01-18 2024-01-17 PS Planned sale

Mates Sharon

Chairman, President & CEO

Executive Director
30,633 -2.8%
66.00
2,021,778 USD 		30,633 -2.8% 66.00 2,021,778 USD
2024-01-18 2024-01-16 PS Planned sale

Mates Sharon

Chairman, President & CEO

Executive Director
5,882 -0.6%
67.76
398,564 USD 		5,882 -0.6% 67.76 398,564 USD
2024-01-18 2024-01-16 PS Planned sale

Mates Sharon

Chairman, President & CEO

Executive Director
65,979 -5.9%
67.25
4,437,088 USD 		65,979 -5.9% 67.25 4,437,088 USD
2024-01-18 2024-01-16 PS Planned sale

Mates Sharon

Chairman, President & CEO

Executive Director
3,500 -0.3%
66.38
232,330 USD 		3,500 -0.3% 66.38 232,330 USD
2024-01-12 2024-01-11 PS Planned sale

Halstead Michael

EVP and General Counsel

Officer
1,486 -100.0%
67.80
100,751 USD 		1,486 -100.0% 67.80 100,751 USD
2024-01-12 2024-01-11 PS Planned sale

Halstead Michael

EVP and General Counsel

Officer
30,360 -95.3%
67.10
2,037,156 USD 		30,360 -95.3% 67.10 2,037,156 USD
2024-01-12 2024-01-11 PS Planned sale

Halstead Michael

EVP and General Counsel

Officer
18,154 -36.3%
66.31
1,203,792 USD 		18,154 -36.3% 66.31 1,203,792 USD
2024-01-04 2024-01-02 PS Planned sale

Durgam Suresh K.

EVP, Chief Medical Officer

Officer
2,210 -100.0%
71.77
158,612 USD 		2,210 -100.0% 71.77 158,612 USD
2024-01-04 2024-01-02 PS Planned sale

Durgam Suresh K.

EVP, Chief Medical Officer

Officer
22,645 -91.1%
70.80
1,603,266 USD 		22,645 -91.1% 70.80 1,603,266 USD
2024-01-04 2024-01-02 PS Planned sale

Durgam Suresh K.

EVP, Chief Medical Officer

Officer
37,427 -60.1%
70.41
2,635,235 USD 		37,427 -60.1% 70.41 2,635,235 USD
2023-12-15 2023-12-13 PS Planned sale

Durgam Suresh K.

EVP, Chief Medical Officer

Officer
21,262 -100.0%
65.00
1,382,030 USD 		21,262 -100.0% 65.00 1,382,030 USD
2023-11-14 2023-11-13 PS Planned sale

Halstead Michael

EVP and General Counsel

Officer
41,067 -100.0%
54.01
2,218,029 USD 		41,067 -100.0% 54.01 2,218,029 USD